α-MSH (Synonyms: α-Melanocyte-Stimulating Hormone, a-MSH) |
Katalog-Nr.GC14374
One-Click Copy Product Info
|
α-MSH(Alpha-melanocyte-stimulating hormone) ist ein Neuropeptid mit immunmodulartorischen Eigenschaften, das durch post-translationale Modifikation von Proopiomelanocortin(POMC) entsteht.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 581-05-5
Sample solution is provided at 25 µL, 10mM.
α-MSH(Alpha-melanocyte-stimulating hormone) ist ein Neuropeptid mit immunmodulartorischen Eigenschaften, das durch post-translationale Modifikation von Proopiomelanocortin(POMC) entsteht. α-MSH koppelt an den MC1R-Rezeptor auf Melanozyten, um die Melanin-Sekretion zu aktivieren, die Bildung von Melanozyten-Dendriten zu fördern und die Melanozyten zu schützen. α-MSH hat eine effektive entzündungshemmende Wirkung auf Immunzellen. Außerdem hemmt α-MSH die IFN-γ-Produktion in antigen-stimulierten T-Zellen[1-3]. α-MSH-stimuliert(1 µM; 72 Stunden) die Melanin-Produktion in B16-Melanomzellen[4]. α-MSH(0-10 ng/mL; 5-10 Minuten) verstärkt die Schutzwirkung unter Stressbedingungen wie UV-Strahlung, dadurch dass es die Melanin-Produktion erhöht und die Mitochondrien-vermittelte Apoptose reduziert[5]. α-MSH(100 nM; 48 Stunden) erhöhte die Tyrosinase-Aktivität und den Melaningehalt um 56.5% bzw. 61.7% und veränderte den Metabolit-Spiegel in Melanomzellen[6].
α-MSH (1mg / kg; i.v; 12 Stunden) kann die Bakterienlast in Mäuse mit Verschluss der Arteria cerebri media(MCAO) erhöhen[7]. α-MSH(500 nM ; i.p; 0-6 Stunden) fördert die Fettsäure-Oxidation in weißem und braunem Fettgewebe(WAT und BAT)[8].
References:
[1]. Ichiyama T, Sato S, et,al. The neuroimmunomodulatory peptide alpha-MSH. Ann N Y Acad Sci. 2000;917:221-6. doi: 10.1111/j.1749-6632.2000.tb05386.x. PMID: 11268347.
[2]. Li C, Wu M, et,al. α- MSH Plays Anti-inflammatory and Anti-fungal Role in Aspergillus Fumigatus Keratitis. Curr Eye Res. 2022 Mar;47(3):343-351. doi: 10.1080/02713683.2021.2006235. Epub 2021 Dec 12. PMID: 34766863.
[3]. Schulte-HerbrÜggen O, Quarcoo D, et,al. Alpha-MSH promotes spontaneous post-ischemic pneumonia in mice via melanocortin-receptor-1. Exp Neurol. 2008 Apr;210(2):731-9. doi: 10.1016/j.expneurol.2008.01.006. Epub 2008 Jan 19. PMID: 18304533.
[4]. Song HS, Sim SS. Acteoside inhibits alpha-MSH-induced melanin production in B16 melanoma cells by inactivation of adenyl cyclase. J Pharm Pharmacol. 2009 Oct;61(10):1347-51. doi: 10.1211/jpp/61.10.0011. PMID: 19814867.
[5]: Choudhary R, Sharma A, et,al. Role of alpha-melanocyte stimulating hormone (α-MSH) in modulating the molecular mechanism adopted by melanocytes of Bos indicus under UVR stress. Mol Cell Biochem. 2020 Feb;465(1-2):141-153. doi: 10.1007/s11010-019-03674-w. Epub 2019 Dec 10. PMID: 31823188.
[6]. Seo SH, Jo JK, et,al. Metabolomics Reveals the Alteration of Metabolic Pathway by Alpha-Melanocyte-Stimulating Hormone in B16F10 Melanoma Cells. Molecules. 2020 Jul 26;25(15):3384. doi: 10.3390/molecules25153384. PMID: 32722640; PMCID: PMC7436294.
[7]. Schulte-HerbrÜggen O, Quarcoo D, et,al. Alpha-MSH promotes spontaneous post-ischemic pneumonia in mice via melanocortin-receptor-1. Exp Neurol. 2008 Apr;210(2):731-9. doi: 10.1016/j.expneurol.2008.01.006. Epub 2008 Jan 19. PMID: 18304533.
[8]. Gan L, Liu Z, et,al. α-MSH and Foxc2 promote fatty acid oxidation through C/EBPβ negative transcription in mice adipose tissue. Sci Rep. 2016 Nov 7;6:36661. doi: 10.1038/srep36661. PMID: 27819350; PMCID: PMC5098202.
| Zellexperiment [1]: | |
Zelllinien | B16 Melanomzellen |
Vorbereitungsmethode | Mit α-MSH behandelten Zellen in Kulturschalen(60 mm) wurden 72 Stunden lang bei 37℃ in einer CO2-Kammer inkubiert. |
Reaktionsbedingungen | 1 µM; 72 Stunden |
Anwendungen | α-MSH stimuliert die Melanin-Produktion in B16-Melanomzellen. |
| Tierversuch [2]: | |
Tiermodelle | 3 Wochen alte männliche C57BL/6J-Mäuse |
Vorbereitungsmethode | Mäusen wurde an 2 Tagen vor Beginn der Dunkelphase einmal täglich entweder PBS oder α-MSH (500 nM) intraperitoneal injiziert. Inguinales Fettgewebe(iWAT) wurde 0.5 h, 1 h, 2 h, 4 h und 6 h nach der letzten Injektion aus der Behandlungsgruppe entnommen. |
Dosierungsform | 500 nM ; i.p; 0-6 Stunden |
Anwendungen | α-MSH fördert die Fettsäure-Oxidation im weißen Fettgewebe(WAT) und im braunen Fettgewebe(BAT). |
| References: [1]. Song HS, Sim SS. Acteoside inhibits alpha-MSH-induced melanin production in B16 melanoma cells by inactivation of adenyl cyclase. J Pharm Pharmacol. 2009 Oct;61(10):1347-51. doi: 10.1211/jpp/61.10.0011. PMID: 19814867. | |
| Cas No. | 581-05-5 | SDF | |
| Überlieferungen | α-Melanocyte-Stimulating Hormone, a-MSH | ||
| Chemical Name | (4S,5Z,7S,8Z,10S,11Z,13S,14Z,16S,17Z,20Z,22S)-7-((1H-imidazol-5-yl)methyl)-16-((1H-indol-3-yl)methyl)-26-amino-10-benzyl-13-(3-guanidinopropyl)-5,8,11,14,17,20-hexahydroxy-22-((S)-2-((Z)-hydroxy(((S)-1-hydroxy-1-imino-3-methylbutan-2-yl)imino)methyl)pyrro | ||
| Canonical SMILES | CC([C@@](/N=C(O)/[C@]1([H])CCCN1C([C@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/C)([H])CO)([H])CC2=CC=C(O)C=C2)([H])CO)([H])CCSC)([H])CCC(O)=O)([H])CC3=CN=CN3)([H | ||
| Formula | C77H109N21O19S | M.Wt | 1664.9 |
| Löslichkeit | 25mg/ml in Water | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 600.6 μL | 3.0032 mL | 6.0064 mL |
| 5 mM | 120.1 μL | 600.6 μL | 1.2013 mL |
| 10 mM | 60.1 μL | 300.3 μL | 600.6 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)